FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:296-298 July 19, 2007 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Sandborn, W. J. Related Article by Schreiber, S. PubMed Citation

For decades, many patients with Crohn's disease required prolonged courses of corticosteroids, repeated surgeries, or both, despite treatment with 5-aminosalicylic acid (mesalamine) or immunomodulators such as azathioprine. The introduction of infliximab, the first antibody against tumor necrosis factor (TNF-), dramatically changed the treatment of patients with Crohn's disease.¹ Administered as an intermittent parenteral therapy, infliximab proved efficacious in patients whose condition was resistant to treatment, and the drug is widely used for such patients. However, the infliximab experience served to reinforce the adage that there often is much to be learned about new medications. We soon discovered that patients . . . [Full Text of this Article]

Source Information

From the Center for Clinical Epidemiology and Biostatistics and the Centers for Education and Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia.

Related Letters:

Anti-TNF Antibodies for Crohn's Disease
Camilleri M., Lewis J. D.
Extract | Full Text | PDF  
N Engl J Med 2007; 357:1662, Oct 18, 2007. Correspondence

This article has been cited by other articles:

• Giansanti, F., Ramazzotti, M., Vannozzi, L., Rapizzi, E., Fiore, T., Iaccheri, B., Degl' Innocenti, D., Moncini, D., Menchini, U. (2008). A Pilot Study on Ocular Safety of Intravitreal Infliximab in a Rabbit Model. IOVS 49: 1151-1156 [Abstract] [Full Text]  
• Camilleri, M., Lewis, J. D. (2007). Anti-TNF Antibodies for Crohn's Disease. NEJM 357: 1662-1662 [Full Text]